FindTrial
Sign In

Meta-analysis of Abraxane used as a neo-adjuvant chemotherapy for operable breast cancer

Meta-analysis of Abraxane used as a neo-adjuvant chemotherapy for operable breast cancer - JBCRG-S01

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000028774
Enrollment
500
Registered
2017-09-01
Start date
2017-10-15
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Operable breast cancer(stage I-III)

Interventions

None listed

Sponsors

Japan Breast Cancer Research Group (JBCRG)
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1)Clinical trial(s) started after July 2010. 2)Principal investigator(s) in each trial agree with participation in this study. 3)Abraxane-containing regimen was used for neoadjuvant chemotherapy in naive operable breast cancer patients. 4)Registered in UMIN with ethical review. 5)Clinical trials in which more than 10 patients participated. 6)Clinical trials that have already been completed (unpublished data are available). 7)To submit the data, each researcher was authorized by each research ethics committee.

Exclusion criteria

Exclusion criteria: Patients who are unwilling to participate in this study.

Design outcomes

Primary

MeasureTime frame
pCR: pathological complete response—

Secondary

MeasureTime frame
Adverse events(>=G3) RDI(Relative dose intensity for Abraxane)—

Countries

Japan,Asia(except Japan)

Contacts

Public ContactJun Fukase

Japan Breast Cancer Research Group (JBCRG) Head office

office@jbcrg.jp03-6264-8873

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026